AbbVie/J&J Withdrawal Of Imbruvica Indications Clears Space For Competitors

The BTK inhibitor’s exit from MCL and MZL after lackluster Phase III confirmatory trial results gives AstraZeneca’s Calquence and BeiGene’s Brukinsa a potential shot at claiming the space.

AbbVie and J&J said they would withdraw two of Imbruvica's lymphoma indications • Source: Shutterstock

The loss of two indications for AbbVie Inc. and Johnson & Johnson’s Imbruvica (ibrutinib), for mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL), are relatively small markets for the BTK inhibitor, but their withdrawal from Imbruvica’s label potentially clears the way for newer BTK inhibitors, provided their confirmatory trials are more successful.

The Janssen Pharmaceutical Companies of J&J and AbbVie’s Pharmacyclics subsidiary said 6 April said they would voluntarily withdraw the US...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category